BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3879016)

  • 1. Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.
    Talmadge JE; Chirigos MA
    Springer Semin Immunopathol; 1985; 8(4):429-43. PubMed ID: 3879016
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimization of an immunotherapeutic protocol with poly(I,C)-LC.
    Talmadge JE; Hartmann D
    J Biol Response Mod; 1985 Oct; 4(5):484-9. PubMed ID: 4078594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic potential in murine tumor models of polyinosinic-polycytidylic acid and poly-L-lysine solubilized by carboxymethylcellulose.
    Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Chirigos M
    Cancer Res; 1985 Mar; 45(3):1066-72. PubMed ID: 3971361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antitumor effect of Corynebacterium parvum and poly ICLC on experimental brain tumors].
    Kiya K; Kitaoka T; Okamoto H; Harada K; Uozumi T; Toge T; Hattori T; Machida H
    Neurol Med Chir (Tokyo); 1983 Nov; 23(11):841-8. PubMed ID: 6201759
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferons and interferon inducers in cancer treatment.
    Krown SE
    Semin Oncol; 1986 Jun; 13(2):207-17. PubMed ID: 2424089
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of recurrent laryngeal papillomatosis with an artificial interferon inducer (poly ICLC).
    Leventhal BG; Kashima H; Levine AS; Levy HB
    J Pediatr; 1981 Oct; 99(4):614-6. PubMed ID: 7277106
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I trials of biological response modifiers.
    Smalley RV; Oldham RK
    Drugs Exp Clin Res; 1986; 12(1-3):31-9. PubMed ID: 3089752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer.
    Theriault RL; Hortobagyi GN; Buzdar AU; Levy HB; Hersh EM
    Cancer Treat Rep; 1986 Nov; 70(11):1341-2. PubMed ID: 3768878
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunostimulants for malignant gliomas.
    Butowski N
    Neurosurg Clin N Am; 2010 Jan; 21(1):53-65. PubMed ID: 19944966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of a modified polyinosinic acid--polycytidylic acid complex against herpes simplex keratitis in monkeys (author's transl)].
    Teranishi H
    Nippon Ganka Gakkai Zasshi; 1980 Sep; 84(9):1198-204. PubMed ID: 7223554
    [No Abstract]   [Full Text] [Related]  

  • 11. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.
    Dillon PM; Petroni GR; Smolkin ME; Brenin DR; Chianese-Bullock KA; Smith KT; Olson WC; Fanous IS; Nail CJ; Brenin CM; Hall EH; Slingluff CL
    J Immunother Cancer; 2017 Nov; 5(1):92. PubMed ID: 29157306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of interferon and poly ICLC, and their possible utility as anti-neoplastic agents in man.
    Levy HB; Levine AS
    Tex Rep Biol Med; 1981-1982; 41():653-62. PubMed ID: 6189230
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)].
    Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
    No To Shinkei; 1982 Mar; 34(3):267-73. PubMed ID: 7093065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary trial of poly(I,C)-LC in multiple sclerosis.
    McFarlin DE; Bever CT; Salazar AM; Levy HB
    J Biol Response Mod; 1985 Oct; 4(5):544-8. PubMed ID: 2416885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed recovery from herpes.
    Roach ES; Abramson J
    Pediatr Infect Dis; 1985; 4(6):703. PubMed ID: 4080594
    [No Abstract]   [Full Text] [Related]  

  • 16. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis.
    Bever CT; Salazar AM; Neely E; Ferraraccio BE; Rose JW; McFarland HF; Levy HB; McFarlin DE
    Neurology; 1986 Apr; 36(4):494-8. PubMed ID: 3960323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortisol induction by poly ICLC: implications for clinical trials of interferon.
    Bever CT; McFarland HF; Levy HB; McFarlin DE
    Ann Neurol; 1988 Feb; 23(2):196-9. PubMed ID: 2454067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
    Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
    J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys.
    Puri SK; Dutta GP; Levy HB; Maheshwari RK
    J Interferon Cytokine Res; 1996 Jan; 16(1):49-52. PubMed ID: 8640451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma.
    Durie BG; Levy HB; Voakes J; Jett JR; Levine AS
    J Biol Response Mod; 1985 Oct; 4(5):518-24. PubMed ID: 3935757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.